Global Personalized Cancer Medicine Market 2023 by Company, Regions, Type and Application, Forecast to 2029

Global Personalized Cancer Medicine Market 2023 by Company, Regions, Type and Application, Forecast to 2029

According to our (Global Info Research) latest study, the global Personalized Cancer Medicine market size was valued at USD 166370 million in 2022 and is forecast to a readjusted size of USD 366720 million by 2029 with a CAGR of 12.0% during review period.

Personalized cancer medicine, also known as targeted therapies or precision medicines, are medications designed to specifically target the unique genetic or molecular characteristics of an individual patient's cancer. These drugs are a central component of personalized cancer medicine and are chosen based on the genomic and molecular profiling of the patient's tumor.

Immunotherapies: While not traditional targeted therapies, immunotherapies like immune checkpoint inhibitors are another form of personalized cancer treatment. These drugs enhance the patient's immune system to recognize and attack cancer cells, and they can be tailored to patients based on their tumor's molecular characteristics.

Personalized cancer treatment drugs have revolutionized cancer care by allowing oncologists to tailor treatment plans to the individual characteristics of each patient's cancer. This approach holds great promise for improving outcomes and reducing the side effects associated with traditional cancer treatments. However, ongoing research and advancements are needed to expand the repertoire of targeted therapies and ensure that they are accessible to more cancer patients.

In the global market, the core manufacturers of Precision Cancer Medicine (Personalised Cancer Medicine) are AbbVie, Johnson & Johnson, Novartis, and others. The top three players within this industry account for about 30% of the market share. North America, Europe, and Asia Pacific are the major manufacturing regions for this product, with North America accounting for over 50% of the global market share. The product can be classified on the basis of treatment into immunotherapy and targeted therapy drugs. The product is widely used in the treatment of lung, breast, prostate, blood and other cancers.

The Global Info Research report includes an overview of the development of the Personalized Cancer Medicine industry chain, the market status of Lung Cancer (Cancer Immunotherapy, Targeted Therapy), Breast Cancer (Cancer Immunotherapy, Targeted Therapy), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Personalized Cancer Medicine.

Regionally, the report analyzes the Personalized Cancer Medicine markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Personalized Cancer Medicine market, with robust domestic demand, supportive policies, and a strong manufacturing base.

Key Features:

The report presents comprehensive understanding of the Personalized Cancer Medicine market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Personalized Cancer Medicine industry.

The report involves analyzing the market at a macro level:

Market Sizing and Segmentation: Report collect data on the overall market size, including the revenue generated, and market share of different by Method (e.g., Cancer Immunotherapy, Targeted Therapy).

Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Personalized Cancer Medicine market.

Regional Analysis: The report involves examining the Personalized Cancer Medicine market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.

Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Personalized Cancer Medicine market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.

The report also involves a more granular approach to Personalized Cancer Medicine:

Company Analysis: Report covers individual Personalized Cancer Medicine players, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.

Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Personalized Cancer Medicine This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Lung Cancer, Breast Cancer).

Technology Analysis: Report covers specific technologies relevant to Personalized Cancer Medicine. It assesses the current state, advancements, and potential future developments in Personalized Cancer Medicine areas.

Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Personalized Cancer Medicine market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.

Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.

Market Segmentation

Personalized Cancer Medicine market is split by Method and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Method, and by Application in terms of value.

Market segment by Method
Cancer Immunotherapy
Targeted Therapy

Market segment by Application
Lung Cancer
Breast Cancer
Prostate Cancer
Blood-related Cancer
Other

Market segment by players, this report covers
AbbVie
Johnson & Johnson
Novartis
Gilead Sciences
Roche
Bristol-Myers Squibb
Amgen
AstraZeneca
Merck & Co
Takeda
Merck KGaA
Seagen
Eli Lilly
Ono Pharmaceutical
Pfizer
GSK
Exelixis
Regeneron
Innovent
Hengrui Medicine

Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
South America (Brazil, Argentina and Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 13 chapters:

Chapter 1, to describe Personalized Cancer Medicine product scope, market overview, market estimation caveats and base year.

Chapter 2, to profile the top players of Personalized Cancer Medicine, with revenue, gross margin and global market share of Personalized Cancer Medicine from 2018 to 2023.

Chapter 3, the Personalized Cancer Medicine competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.

Chapter 4 and 5, to segment the market size by Method and application, with consumption value and growth rate by Method, application, from 2018 to 2029.

Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023.and Personalized Cancer Medicine market forecast, by regions, method and application, with consumption value, from 2024 to 2029.

Chapter 11, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.

Chapter 12, the key raw materials and key suppliers, and industry chain of Personalized Cancer Medicine.

Chapter 13, to describe Personalized Cancer Medicine research findings and conclusion.